Please assess the completion status of the following clinical trial:

Trial Title: MEtronomic TrEatment Option in Advanced bReast cAncer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed HER2-negative locally advanced or metastatic (stage IV) breast cancer.~* Maximum of one prior line of chemotherapy for advanced or metastatic breast cancer.~* Measurable or non-measurable, but radiologically evaluable (except for skin lesions), disease according to RECIST 1.1 criteria.~* Female aged 18 years or older.~* Life expectancy \> 3 months.~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.~* ER-positive disease by local laboratory, determined on most recent available tissue (latest biopsy of metastatic lesion, otherwise prior biopsy or surgical specimen).~* If previously treated with a taxane in the neoadjuvant or adjuvant setting, the period from end of treatment to disease recurrence must have been \> 12 months (\> 365 days).~* Radiation therapy, if given and regardless of site, must be completed at least 2 weeks prior to randomization.~* Normal hematologic status,~* Absolute neutrophil count ≥1000/mm3 (1.0 × 109/L),~* Platelets ≥ 100 × 109/L,~* Hemoglobin ≥ 9 g/dL (≥ 90 g/L).~* Normal renal function: serum creatinine ≤ 1.5 ULN or calculated creatinine clearance ≥ 50 mL/min according to the Cockcroft-Gault formula.~* Normal liver function:~* Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN). In the case of known Gilbert's syndrome, a higher serum total bilirubin (\< 3 × ULN) is allowed.~* Aspartate transaminase (AST) and Alanine transaminase (ALT) ≤ 3 × ULN; if the patient has liver metastases, ALT and AST must be ≤ 5 × ULN.~* Women of child bearing potential must have documented negative pregnancy test within 2 weeks prior to randomization and agree to acceptable birth control (non-hormonal) during and up to 6 months after trial therapy.~* Written Informed Consent (IC) must be signed and dated by the patient and the Investigator prior to starting screening procedures and randomization.~* The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.~Exclusion Criteria:~* More than one prior line of chemotherapy for advanced or metastatic breast cancer~* Previous treatment for advanced or metastatic disease with taxanes, or capecitabine or vinorelbine or oral cyclophosphamide.~* More than 2 lines of previous endocrine therapy for locally advanced or metastatic breast cancer.~* Known active central nervous system metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (patients with history of Central Nervous System (CNS) metastases or spinal cord compression are eligible if they are clinically and radiologically stable for at least 4 weeks before first dose of trial treatment and have not required high-dose steroid treatment in the last 4 weeks).~* Peripheral neuropathy grade 2 or higher (CTCAE version 4.0).~* Significant uncontrolled cardiac disease (i.e. unstable angina, myocardial infarction within prior 6 months), patients classified as having a New York Heart Association (NYHA) class III or IV congestive heart failure.~* Pregnant or lactating.~* Prior history of non-breast malignancy (except for adequately controlled basal cell carcinoma of the skin, carcinoma in situ of the cervix, in situ carcinoma of the bladder).~* Any concurrent condition which in the Investigator's opinion makes it inappropriate for the patient to participate in the trial or which would jeopardize compliance with the protocol.~* Contraindications or known hypersensitivity to the trial medication or excipients.~* The use of any anti-cancer investigational agents within 30 days prior to expected start of trial treatment.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Paclitaxel 90 mg/m2 days 1, 8, 15 q4w. Patients will continue to receive assigned treatment until progression or lack of tolerability.
- Arm B (Type: EXPERIMENTAL): Metronomic VEX:~Cyclophosphamide 50 mg orally once daily continuously, Capecitabine 500 mg, orally 3 times a day (1500 mg/day) continuously, Vinorelbine 40 mg orally days 1, 3, 5 each week continuously. Patients will continue to receive assigned treatment until progression or lack of tolerability.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete